SHERWIN IMPERIO: Open Payments
NPI 1225565104 · LONG BEACH, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$467 in 17 payments from 8 companies in 2025. Trend: 2023 $2,458 · 2024 $1,867 · 2025 $467
Food & beverage: $467
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $190 |
| Teva Pharmaceuticals USA, Inc. | 2 | $62 |
| Vanda Pharmaceuticals Inc. | 2 | $48 |
| Neurocrine BioSciences, Inc. | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Janssen Pharmaceuticals, Inc | 1 | $38 |
| ABBVIE INC. | 1 | $26 |
| Novo Nordisk Inc | 1 | $14 |
Products named: CAPLYTA, AUSTEDO XR, FANAPT, INGREZZA, REXULTI, SPRAVATO, VRAYLAR, Wegovy.
Industry payments across CA — which companies pay providers there.
